Lewy body change and limbic-predominant age-related TDP-43 encephalopathy (LATE) change pulled cognitive trajectories in opposite directions in a retrospective autopsy study of 77 people with intermediate to high Alzheimer's disease neuropathological change, published in Frontiers in Aging Neuroscience on 17 April 2026. Of the 77, 38 (49.4 per cent) had Lewy body change and 39 (50.6 per cent) had LATE change. Using linear mixed effects models, Koo and colleagues report that Lewy body change was associated with faster decline on the Mini-Mental State Examination, the ADAS-Cog 13, the Boston Naming Test, delayed recall on the Rey Auditory Verbal Learning Test and category fluency, covering global cognition, memory, language and executive function. LATE change was associated with a slower decline on the Boston Naming Test. Neither co-pathology altered the longitudinal course of neuropsychiatric symptoms measured with the NPI-Q.

The participants came from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a long-running North American observational study. As of July 2024, autopsy data were available for 110 ADNI subjects; 85 met the threshold for intermediate to high Alzheimer's pathology, three were dropped for missing TDP-43 assessment and four for fewer than two years of follow-up before death, leaving 77. Models were adjusted for baseline age, sex, years of education, APOE4 carrier status and dementia diagnosis at baseline, and baseline analyses were corrected for multiple comparisons. At baseline, Lewy body change was not associated with cognition or neuropsychiatric symptoms, while LATE change was associated with better Trail Making Test performance and less severe sleep disturbance.

The direction-of-effect split is what makes the series notable. Mixed pathology is common in Alzheimer's disease, and both extra proteins, alpha-synuclein in Lewy bodies and TDP-43 in LATE, are found routinely at autopsy alongside amyloid plaques and tau tangles. The faster decline linked to Lewy body change is consistent with earlier ADNI work: a 2024 analysis in Nature Communications of 795 cognitively impaired participants, using an alpha-synuclein seed amplification assay rather than autopsy, reported that Lewy body pathology was associated with greater hypometabolism and faster cognitive decline. The authors argue their findings support stratifying Alzheimer's patients by comorbid neuropathology.

The counterpoint is size and design. Seventy-seven brain donors is a small series, the groups overlap because a person may carry both co-pathologies, and the LATE group had longer follow-up than those without it, while the Lewy body group had shorter follow-up and more APOE4 carriers. A slower measured decline in naming is not evidence that TDP-43 protects anyone; it is one test score trajectory in one cohort, and ADNI volunteers are not representative of the general population. There is also no validated way to detect LATE change in a living person, so the stratification the authors call for is not yet available in the clinic.